#Endocrinology #GLP1 #FDA #DiabetesCare #MedTech #HealthcarePolicy Considering FDA has already approved a number of genuine generics for exenatide and liraglutide (at least two of the latter have been approved for the indication of obesity), the need for "compounded" GLP-1 drugs is questionable anyway
Some early clinical findings suggest that patients with autoimmune conditions may experience less joint stiffness and fewer inflammatory symptoms when GLP-1 is part of their treatment plan, though ongoing research is still needed
[1] [9] Although the primary endpoints focused on body weight reduction, secondary analyses provided data on hepatic fat content, measured using magnetic resonance imaging-proton density fat fraction (MRI-PDFF) a validated, reference-standard non-invasive technique for quantifying liver fat
Nevertheless, she boasted that the findings suggest that it is important to continue studying semaglutide as a possible new treatment for the epidemic that took more than 100,000 lives last year in the United States
Yang H, Liu Y, Bai F, Zhang J-Y, Ma S-H, Liu J, et al
So just as a recap, GLP ones can have tremendous benefits when used correctly in menopause and maybe even perimenopause